Sweden-based Cantargia's antibody CAN04 (nidanilimab) is being investigated in an open label, three-armed phase IIa clinical trial, called CANFOUR, it was reported on Friday.

The product is being examined as monotherapy or in chemotherapy combinations in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC). All 20 patients planned for one of these arms, monotherapy, have now commenced treatment at 10mg/kg. The company says that overall, the safety has been good and in line with the results from the phase one trial.

The monotherapy results including biomarkers and efficacy are likely to be ready during the fourth quarter of this year. The company plans to use the opportunity to include additional patients to generate safety and biomarker data at a higher dose level. In parallel to the monotherapy, recruitment is ongoing for the combination arms.